PreDxion Bio

PreDxion Bio was developing a rapid, saliva-based antigen test designed for the detection of the SARS-CoV-2 S-protein, targeting asymptomatic and presymptomatic individuals. Their core innovation centered around the ability to scale production to tens of millions of tests within days, utilizing semiconductor fabrication processes. This level of scalability was intended to provide public health officials and policymakers with the necessary data for effective contact tracing and informed decision-making.

Initially, PreDxion Bio's technology stemmed from critical care applications. Their original platform was a rapid, near real-time system for detecting cytokines and biomarkers, aimed at monitoring the immune responses of critically ill patients. This platform was based on a novel sensor technology originating from the University of Michigan. PreDxion Bio had received FDA Breakthrough Device designation and collaborated with leading pharmaceutical companies to monitor immune responses following CAR-T therapy, predict cytokine release syndrome and neurological adverse events, and guide precision medicine strategies in critical care settings.